{"doi":"10.1056/nejmoa2117608","title":"Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S","abstract":"BACKGROUND: The Ad26.COV2.S vaccine was highly effective against severe-critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis. METHODS: viral particles) or placebo. The primary end points were vaccine efficacy against moderate to severe-critical Covid-19 with onset at least 14 days after administration and at least 28 days after administration in the per-protocol population. Safety and key secondary and exploratory end points were also assessed. RESULTS: Median follow-up in this analysis was 4 months; 8940 participants had at least 6 months of follow-up. In the per-protocol population (39,185 participants), vaccine efficacy against moderate to severe-critical Covid-19 at least 14 days after administration was 56.3% (95% confidence interval [CI], 51.3 to 60.8; 484 cases in the vaccine group vs. 1067 in the placebo group); at least 28 days after administration, vaccine efficacy was 52.9% (95% CI, 47.1 to 58.1; 433 cases in the vaccine group vs. 883 in the placebo group). Efficacy in the United States, primarily against the reference strain (B.1.D614G) and the B.1.1.7 (alpha) variant, was 69.7% (95% CI, 60.7 to 76.9); efficacy was reduced elsewhere against the P.1 (gamma), C.37 (lambda), and B.1.621 (mu) variants. Efficacy was 74.6% (95% CI, 64.7 to 82.1) against severe-critical Covid-19 (with only 4 severe-critical cases caused by the B.1.617.2 [delta] variant), 75.6% (95% CI, 54.3 to 88.0) against Covid-19 leading to medical intervention (including hospitalization), and 82.8% (95% CI, 40.5 to 96.8) against Covid-19-related death, with protection lasting 6 months or longer. Efficacy against any severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was 41.7% (95% CI, 36.3 to 46.7). Ad26.COV2.S was associated with mainly mild-to-moderate adverse events, and no new safety concerns were identified. CONCLUSIONS: A single dose of Ad26.COV2.S provided 52.9% protection against moderate to severe-critical Covid-19. Protection varied according to variant; higher protection was observed against severe Covid-19, medical intervention, and death than against other end points and lasted for 6 months or longer. (Funded by Janssen Research and Development and others; ENSEMBLE ClinicalTrials.gov number, NCT04505722.).","journal":"New England Journal of Medicine","year":2022,"id":232158,"datarank":4.554790011673384,"base_score":5.529429087511423,"endowment":5.529429087511423,"self_citation_contribution":0.8294143631267137,"citation_network_contribution":3.72537564854667,"self_endowment_contribution":0.8294143631267137,"citer_contribution":3.72537564854667,"corpus_percentile":null,"corpus_rank":null,"citation_count":251,"citer_count":100,"citers_with_citation_signal":100,"citers_with_endowment":100,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9352,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT04505722"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":314444,"name":"Glenda Gray","orcid":"0000-0003-4649-1477","position":1,"is_corresponding":false},{"id":306146,"name":"An Vandebosch","orcid":null,"position":2,"is_corresponding":false},{"id":806015,"name":"Vicky Cárdenas","orcid":null,"position":3,"is_corresponding":false},{"id":805337,"name":"Georgi Shukarev","orcid":"0000-0001-5154-7047","position":4,"is_corresponding":false},{"id":314047,"name":"Beatriz Grinsztejn","orcid":"0000-0003-3692-5155","position":5,"is_corresponding":false},{"id":240555,"name":"Paul Goepfert","orcid":"0000-0001-8441-5737","position":6,"is_corresponding":false},{"id":503687,"name":"Carla Truyers","orcid":null,"position":7,"is_corresponding":false},{"id":842958,"name":"Ilse Van Dromme","orcid":null,"position":8,"is_corresponding":false},{"id":306134,"name":"Bart Spiessens","orcid":null,"position":9,"is_corresponding":false},{"id":841718,"name":"Johan Vingerhoets","orcid":"0000-0001-5939-9501","position":10,"is_corresponding":false},{"id":107620,"name":"Jerome Custers","orcid":"0000-0002-7151-8654","position":11,"is_corresponding":false},{"id":805338,"name":"Gert C. Scheper","orcid":"0000-0003-2316-756X","position":12,"is_corresponding":false},{"id":288619,"name":"Merlin L. Robb","orcid":"0000-0003-3949-9649","position":13,"is_corresponding":false},{"id":324517,"name":"John J. Treanor","orcid":null,"position":14,"is_corresponding":false},{"id":842959,"name":"Martin Ryser","orcid":null,"position":15,"is_corresponding":false},{"id":106527,"name":"Dan H. Barouch","orcid":"0000-0001-5127-4659","position":16,"is_corresponding":false},{"id":331742,"name":"Edith Swann","orcid":"0000-0001-7791-9232","position":17,"is_corresponding":false},{"id":593569,"name":"Mary Marovich","orcid":"0000-0002-8400-3748","position":18,"is_corresponding":false},{"id":38212,"name":"Kathleen M. Neuzil","orcid":"0000-0001-9480-2714","position":19,"is_corresponding":false},{"id":96348,"name":"Lawrence Corey","orcid":"0000-0002-2179-2436","position":20,"is_corresponding":false},{"id":841719,"name":"Jeffrey J. Stoddard","orcid":"0000-0001-7232-3800","position":21,"is_corresponding":false},{"id":842960,"name":"Karin Hardt","orcid":null,"position":22,"is_corresponding":false},{"id":59380,"name":"Javier Ruiz‐Guiñazú","orcid":"0000-0001-6941-3100","position":23,"is_corresponding":false},{"id":573137,"name":"Mathieu Le Gars","orcid":null,"position":24,"is_corresponding":false},{"id":40994,"name":"Hanneke Schuitemaker","orcid":"0000-0001-8563-2266","position":25,"is_corresponding":false},{"id":107635,"name":"Johan Van Hoof","orcid":null,"position":26,"is_corresponding":false},{"id":618178,"name":"Frank Struyf","orcid":"0000-0001-9988-0260","position":27,"is_corresponding":false},{"id":303949,"name":"Macaya Douoguih","orcid":"0000-0002-2707-5729","position":28,"is_corresponding":false},{"id":328876,"name":"Jerald Sadoff","orcid":"0000-0002-4839-3013","position":0,"is_corresponding":true}],"reference_count":23,"raw_metadata":null,"created_at":"2026-07-19T00:21:12.348693Z","pmid":"35139271","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}